Belagenpumatucel-L for the treatment of non-small cell lung cancer

Erika Rijavec, Federica Biello, Carlo Genova, Giulia Barletta, Claudia Maggioni, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Irene Vanni, Angela Alama, Sabrina Beltramini, Maria Attilia Grassi, Francesco Boccardo, Francesco Grossi

Research output: Contribution to journalArticlepeer-review


Introduction: Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene.Areas covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.Expert opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.

Original languageEnglish
Pages (from-to)1371-1379
Number of pages9
JournalExpert Opinion on Biological Therapy
Issue number9
Publication statusPublished - Sep 2 2015


  • Belagenpumatucel-L
  • TGF-b2
  • vaccines

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery


Dive into the research topics of 'Belagenpumatucel-L for the treatment of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this